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Abstract 23
Neuronal activity in the brain is regulated by an excitation-inhibition balance. Glutamate 24 is the main excitatory neurotransmitter. Transcranial magnetic stimulation (TMS) 25 evoked electroencephalographic (EEG) potentials (TEPs) represent a novel way to 26 quantify pharmacological effects on neuronal activity in the human cortex. Here we 27
tested TEPs under the influence of a single oral dose of two anti-glutamatergic drugs, 28 perampanel, an AMPA-receptor antagonist, and dextromethorphan, an NMDA-29 receptor antagonist, and nimodipine, an L-type voltage-gated calcium channel blocker 30 in 16 healthy adults in a pseudorandomized, double-blinded, placebo-controlled, 31 crossover design. Single-pulse TMS was delivered to the left motor cortex and TEPs 32 were obtained pre-and post-drug intake. Dextromethorphan specifically increased the 33 amplitude of the N45, a negative potential around 45 ms after the TMS pulse, while 34 perampanel reduced the P70 amplitude in the non-stimulated hemisphere. Nimodipine 35 and placebo had no effect on TEPs. These data extend previous pharmaco-TMS-EEG 36 studies by demonstrating that the N45 is regulated by a balance of GABAAergic 37 inhibition and NMDA-receptor-mediated glutamatergic excitation. In contrast, AMPA-38 receptor-mediated glutamatergic neurotransmission contributes to 39 interhemispherically propagated activity reflected in the P70. These data are important 40
Introduction 43
Transcranial magnetic stimulation (TMS) evoked electroencephalographic (EEG) 44 potentials (TEPs) reflect excitability and effective connectivity of the human brain 45 (Ilmoniemi and Kicic 2010; Rogasch and Fitzgerald 2013; Chung et al. 2015; Tremblay 46 et al. 2019 ). However, the exact physiological mechanisms underlying the multiple 47 TEPs evoked by, e.g., motor cortex stimulation (Bonato et al. 2006; Lioumis et al. 48 2009) remain still largely elusive. Pharmaco-TMS-EEG has demonstrated that the 49 N45, a negative potential around 45 ms after the TMS pulse, is regulated by 50
GABAAergic inhibition as its amplitude is enhanced by allosteric positive modulators 51 at GABAA receptors, such as benzodiazepines and zolpidem (Premoli et al. 2014; 52 Premoli et al. 2018) , but reduced by the experimental compound S44819 (Darmani et 53 al. 2016 ), a specific antagonist at the alpha-5 subtype of the GABAA receptor. In 54 contrast, GABABergic inhibition contributes to the N100, as its amplitude at the site of 55 the stimulated motor cortex is increased by baclofen, a specific GABAB receptor 56 agonist (Premoli et al. 2014; Premoli et al. 2018 Here, we investigated the effects of a single oral dose of two anti-glutamatergic drugs 73 (perampanel, dextromethorphan) and the L-type voltage-gated calcium channel (L-74 VGCC) blocker nimodipine (Hess et al. 1984) on TEPs in healthy subjects in a 75 pseudorandomized double-blind placebo-controlled crossover design. Perampanel is 76 a selective, non-competitive postsynaptic α-amino-3-hydroxy-5-methyl-4-isoxazole 77
propionic acid (AMPA) receptor antagonist (Rogawski and Hanada 2013) . 78
Dextromethorphan is a prodrug whose active metabolite, dextrorphan, acts as a non-79 competitive N-methyl-D-aspartate (NMDA) receptor antagonist (Wong et al. 1988) . 80
AMPA and NMDA receptors are the main ionotropic receptors for glutamate in the 81 central nervous system. AMPA receptor-mediated currents generate fast excitatory 82 postsynaptic potentials (EPSPs), while NMDA receptor activation provides a prolonged 83 EPSP that can last several hundred milliseconds. Action potential generation is largely 84 controlled by AMPA receptor de/activation, while the longer kinetics of NMDA 85 receptors enable spatial and temporal summation of postsynaptic potentials (Niciu et 86 al. 2012) . Accordingly, perampanel is used as an antiepileptic drug (Faulkner 2017), 87 while dextromethorphan has demonstrated efficacy in reducing synaptic plasticity in 88 human cortex (Stefan et al. 2002; Wankerl et al. 2010; Weise et al. 2017 ). Finally, L-89
VGCCs are not significantly involved in controlling the release of glutamate from 90 presynaptic nerve terminals (Catterall 2011) but block synaptic plasticity in human 91 cortex (Wolters et al. 2003; Wankerl et al. 2010; Weise et al. 2017) , probably through 92 inhibition of calcium flux into depolarized postsynaptic cells (Igelmund et al. 1996) . 93
We had no specific hypotheses as to the effects of these study drugs on TEP 94 amplitudes, given that pharmaco-TMS-EEG is a nascent field. Therefore, the study is 95 exploratory, but positive findings would significantly enhance our understanding of the 96 mechanisms underlying TEPs, since the effects of anti-glutamatergic drugs and VGCC 97 blockers have not been tested in this context. 98 6
Material und methods 99
Participants 100
Eighteen male participants (mean age ± SD: 26.0 ± 3.5 years, range: 22-36 years), 101
were included in this study. All subjects underwent physical and neurological 102 examination, and were screened for possible contraindications to TMS (Rossi et al. 103 2009) and to the study medication. Inclusion criteria were written informed consent, 104 right-handedness (mean laterality score ± SD: 88 ± 15 % according to the Edinburgh 105 Inventory (Oldfield 1971)) and male gender, to avoid possible effects of the menstrual 106 cycle on cortical excitability (Smith et al. 1999) . Exclusion criteria were: presence or 107 history of neurologic and psychiatric disease, use of illicit or recreational drugs, 108 smoking, and a history of low blood pressure (assessed with history of past 109 measurements or symptoms, e.g. syncope). The study was approved by the Ethics 110
Committee of the Medical Faculty of Eberhard-Karls-University Tübingen (registration 111 number 526/2014BO1). Sixteen subjects completed all the experimental sessions. 112
One participant did not finish the study due to medical conditions unrelated to the study 113 and one other subject dropped out during the measurements. Therefore, the data 114 analyses are based on 16 subjects. 115
Experimental design 116
A combined pharmaco-TMS-EEG approach (Premoli et al. 2014; Darmani et al. 2016 ) 117 with a pseudorandomized, placebo-controlled, double-blinded crossover design was 118 employed to study the acute effects of perampanel, dextromethorphan and nimodipine 119 on TEP amplitudes. 120
Each experimental session consisted of one pre-and one post-drug measurement, 121 which involved the same procedures, as follows. Before each measurement, resting 122 motor threshold (RMT), defined as the minimum intensity sufficient to elicit an MEP 7 amplitude  50 V in at least five out of ten trials was determined, using the relative 124 frequency method (Groppa et al. 2012) . Then, resting-state EEG (3 min eyes open) 125 was recorded, followed by the delivery of 150 single monophasic TMS pulses with a 126 random interstimulus interval of 5 ± 1 s for TEP recordings. The TMS target was the 127 hand area of the left primary motor cortex (M1), a constant coil position was maintained 128 throughout the experiment. The pre-and post-drug measurements were separated by 129 the administration of the study drug, immediately after the pre-drug measurements, 130 and a pause, which allowed the drug to reach peak serum level (see Supplementary  131 Material and Fig. 1 ). Due to different pharmacokinetics, drugs and/or placebo were 132 applied at two different time points to ensure a double-blinded design. 
137
During the two-hour medication pause two drug administrations were performed (see Supplementary   138 Table 2). One hour after the second drug administration, the post-drug measurements were obtained in 139 the same sequence as the pre-drug measurements. Blood pressure was monitored throughout the 140 measurement.
141
Participants received a single oral dose of perampanel (12 mg/6 mg, Fycompa®, Eisai 142 Pharma), dextromethorphan (120 mg, Hustenstiller-ratiopharm® Dextromethorphan, 143 ratiopharm GmbH), nimodipine (30 mg, Nimodipin-Hexal®, Hexal AG), or placebo (P-144 Tabletten Lichtenstein; Placebo Kapseln). Drug dosages employed in the study are 145 8 approved for medical use. The order of drugs was pseudorandomized and balanced 146 across subjects. Based on drug pharmacokinetics reported in the literature the study 147 drugs are characterized by different peak-plasma times ( Supplementary Table 1 ). 148 Accordingly, study drugs and placebo were given at the two time points indicated in 149 Supplementary Table 2 . To avoid carry-over drug effects, consecutive sessions in each 150 participant were separated by at least two weeks. 151
TMS-EEG and EMG data recordings 152
All participants were seated in a comfortable reclining chair throughout pre-and post-153 RMT was re-tested at the beginning of the post-drug measurements (Fig. 1) and, if 188 different from pre-drug RMT, TMS intensity was adjusted to keep the re-afferent 189 signals similar across pre-and post-drug measurements. The inter-trial interval was 5 190 s ± 25 % random variation to limit habituation. applying the same procedure on the data randomized across the pre-drug vs. post-238 drug measurements. We used 1500 randomizations to obtain the reference distribution 239 and rejected the null hypothesis with p < 0.05 if less than 5 % of the permutations used 240 to construct the reference distribution yielded a maximum cluster-level t-value larger 241 than the one observed in the original data. The same cluster-based approach was 242 used to assess differences between TEPs in the pre-drug measurements of the four 243 drug conditions. To adjust for multiple comparisons, a Bonferroni correction was 244 applied to the obtained p-value. 245
A repeated measure analysis of variance (rmANOVA) with the within-subject effects of 246 DRUG (4 levels: perampanel, dextromethorphan, nimodipine, placebo) and TIME (2 247 levels: pre-drug, post-drug) was run on the RMT and MEP amplitude data. The 248
Shapiro-Wilk test was applied to test for normal distribution. The MEP data were log-249 transformed to achieve normal distribution. Sphericity was checked using Mauchly's 250 test and, whenever violated, the Greenhouse-Geisser correction of the degrees of 251 freedom was applied. For all tests, the significance level was set to p < 0.05. 252
253

Results
254
TMS was well tolerated by all subjects. In one case, a dosage of 12 mg perampanel 255 caused dizziness, nausea and ataxia, which led to reduction of the dosage to 6 mg for 256 the remaining 13 subjects (i.e., 3 of the reported subjects received 12 mg, the other 13 257 subjects received 6 mg of perampanel). Otherwise, drugs were well tolerated by all 258 subjects, apart from minor nausea and slight dizziness reported after perampanel and 259 dextromethorphan intake. 260 261
Drug effects on RMT and MEP amplitude 262
The rmANOVA on RMT values revealed a significant DRUG*TIME interaction (F3,45 = 263 8.993, p < 0.001). Post hoc paired t-tests demonstrated a mean RMT increase (post-264 drug/pre-drug) ± SD after perampanel (1.09 ± 0.08; t15 = 4.11, p < 0.001) and 265 nimodipine (1.04 ± 0.04; t15 = 2.91, p = 0.007) but not dextromethorphan (0.99 ± 0.07, 266 t15 = 0.94, p = 0.36), with compared to RMT change under placebo (0.97 ± 0.07). 267 Importantly, the rmANOVA did not reveal any significant effects of DRUG, TIME or 268 interaction DRUG*TIME on MEP amplitude (Table 1) . 269 
TEPs 272
Pre-drug TEPs and their topographical distributions (Fig. 2) were consistent with 273 previous studies of single pulse TMS over M1 (Komssi et al. 2004b; Bonato et al. 2006; 274 Premoli et al. 2014; Darmani et al. 2016) . Pre-drug TEPs did not differ between the 275 four drug conditions (all pairwise comparisons, p > 0.05). 276
In the placebo and nimodipine conditions there was no significant difference in the 277 post-drug vs. pre-drug measurement in any of the five TOIs (all p > 0.05; Fig. 3) . 278
Perampanel resulted in a decrease of the P70 amplitude (p = 0.002; Fig. 3A, B ). This 279 difference was expressed in predominantly in EEG channels in the non-stimulated 280 hemisphere (Fig. 4B, top row) . Dextromethorphan increased the N45 amplitude (p = 281 0.027; Fig. 3) . The difference was expressed in a bilateral pericentral cluster of 282 electrodes in the stimulated and non-stimulated hemisphere (Fig. 4B, bottom row) . 
312
Error bars indicate mean ±1 SEM.
313
Discussion 314
In this study, we investigated modulation of TMS-evoked EEG potentials by a single 315 oral dose of an AMPA receptor antagonist (perampanel), an NMDA receptor antagonist 316 (dextromethorphan), and an L-VGCC blocker (nimodipine). Perampanel decreased the 317 P70 amplitude, whereas dextromethorphan increased the N45 amplitude. Nimodipine 318 and placebo had no effect on TEP amplitudes. Our results show specific modulation 319 resulting from drugs that act on glutamate receptors. The differential effects are likely 320 caused by differences in the specific modes of drug action, as discussed in detail 321 below. 322
N45 modulation by dextromethorphan 323
Dextromethorphan binds preferentially to NMDA receptors and reduces EPSPs due to 324 inhibition of calcium influx. In paired-pulse TMS-EMG studies, dextromethorphan 325 decreased intracortical facilitation (Ziemann et al. 1998 ), a marker of glutamatergic 326 neurotransmission (Ziemann et al. 2015) , while it did not affect RMT or MEP amplitude 327 (Ziemann et al. 1998; Fitzgerald et al. 2005; Wankerl et al. 2010) . This pattern of effects 328 on TMS-EMG measures is like the one of benzodiazepines, which also reduce 329 intracortical facilitation (Ziemann et al. 1996; Ziemann et al. 2015) , probably through 330 enhancement of short-interval intracortical inhibition, a marker of GABAAergic 331 inhibitory postsynaptic potentials (IPSPs) that superimposes with intracortical 332 facilitation (Hanajima et al. 1998) . At the level of TMS-EEG measurements, 333 dextromethorphan showed a virtually identical effect as benzodiazepines (Premoli et 334 al. 2014; Premoli et al. 2018 ) by increasing the N45 amplitude (cf. Fig. 6 ). Therefore, 335 the present data lead to the proposition that the N45 amplitude reflects excitation-336 inhibition balance of EPSPs and IPSPs evoked by the TMS pulse. This significantly 337 extends the previous view that the N45 amplitude exclusively reflects GABAAergic 338 inhibition (Premoli et al. 2014; Darmani et al. 2016; Premoli et al. 2018) . 339
Of note, while the enhancing effects of the NMDA receptor antagonist 340 dextromethorphan and benzodiazepines on the N45 amplitude are similar, 341 dextromethorphan (and perampanel) had no effect on the N100 amplitude in the non-342 stimulated hemisphere, while benzodiazepines decreased it (Premoli et al. 2014; 343 Premoli et al. 2018) . Together, these findings support the idea that the N100 in the 344 frontal cortex of the non-stimulated hemisphere reflects propagated neural activity 345 controlled by GABAAergic but not glutamatergic neurotransmission. 
352
P70 modulation by perampanel 353
AMPA receptor activation in response to glutamate binding generates fast EPSPs 354 followed by rapid current decay (Niciu et al. 2012) . The effect of the AMPA receptor 355 antagonist perampanel was specific by reducing the P70 amplitude. Importantly, this 356 effect was almost exclusively expressed in the non-stimulated right hemisphere (cf. 357 Fig. 4 ), suggesting that the effect of perampanel is specific on interhemispherically 358 propagated neural activity. This finding is in close agreement with intrahemispheric and 359 interhemispheric spread of epileptiform activity in rodent cortical slices that was not 360 influenced by application of the NMDA receptor antagonist D-2-amino-5-361 phosphonovaleric acid (D-APV), but blocked by the AMPA receptor antagonist 6-362 cyano-7-nitroquinoxaline-2,3-dione (CNQX) (Alefeld et al. 1998; Telfeian and Connors 363 1999) . The P70 has not shown reactivity to any other of the so far tested drugs (positive 364 allosteric modulators at the GABAA receptor, alpha-5 GABAA receptor antagonist, 365 GABAB receptor agonist, voltage-gated sodium channel blockers, NMDA receptor 366 antagonist, L-VGCC blocker) (Premoli et al. 2014; Darmani et al. 2016; Premoli et al. 367 2017; Premoli et al. 2018) . We therefore propose that the P70 amplitude reflects 368 glutamatergic (interhemispheric) signal propagation mediated by AMPA receptor 369 activation. Whether the P70 amplitude is exaggerated in epilepsy, and may be used 370 as a biomarker to predict antiepileptic drug responses, is currently unclear, as the very 371 few available TEP studies were performed exclusively in patients with generalized 372 epilepsies on antiepileptic drug treatment, without alteration of the P70 amplitude 373 (Julkunen et al. 2013; Ter Braack et al. 2016; Kimiskidis et al. 2017) . to obtain a nimodipine effect on TEPs due to a too low dosage can be largely excluded, 385
as the same single oral dose of 30 mg resulted in significant suppression of long-term 386 potentiation and long-term depression-like plasticity in human motor cortex (Wolters et 387 al. 2003; Wankerl et al. 2010; Weise et al. 2017) . 388
Conclusions 389
Findings support the general notion that TEPs evoked by single-pulse TMS of M1 can 390 be used as markers of excitability and propagated neural activity in the human brain. 391
Specifically, the effects of the NMDA receptor antagonist dextromethorphan extend 392 our understanding of the N45 potential to reflect excitation-inhibition balance regulated 393 by NMDA and GABAA receptors. Furthermore, the suppressive effects of perampanel 394 on the P70 potential in the non-stimulated hemisphere support the idea that this 395 propagated activity is controlled by glutamatergic neurotransmission through AMPA 396 receptors. Finally, the null effects of the L-VGCC blocker nimodipine on TEPs are in 397 accord with the known physiology of L-VGCCs on neuronal excitability. Altogether, 398 pharmaco-TMS-EEG advances our knowledge of the physiology underlying TEPs, and 399 this may be of directly utility in interpreting TEP abnormalities in neurological and 400 psychiatric disorders with pathological neural excitability or signal propagation in brain 401 networks. 402 403
